“Short-Term Efficacy and Safety of Abrocitinib by Baseline Disease Severity in Patients With Moderate-to-Severe Atopic Dermatitis”. 2023. SKIN The Journal of Cutaneous Medicine 7 (2): s154. https://doi.org/10.25251/skin.7.supp.154.